Full Press Release Details
Appoints James E. Dentzer to its Board of Directors
of Curis brings extensive biopharmaceutical financial experience to the Board
N.J. (October 3, 2022) - Imunon, Inc. (Nasdaq: IMNN), a clinical-stage drug development company, announces the appointment
of James E. Dentzer to its Board of Directors, effective immediately. Mr. Dentzer is the chief executive officer of Curis, Inc., a biotechnology
company focused on the development of innovative therapeutics for the treatment of cancer, and brings to Imunon more than 20 years of
leadership in the global pharmaceutical industry. His appointment brings the number of Directors to nine.
Dentzer has been President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. since September 2018. From
March 2018 to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and Chief Financial Officer. From March 2016
to March 2018, Mr. Dentzer served as Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer has also held
the positions of secretary and treasurer from March 2016 to March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial
Officer of Dicerna Pharmaceuticals, Inc., a biotechnology company, from December 2013 to December 2015. Prior to that, he was the Chief
Financial Officer of Valeritas, Inc., a medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc.,
he was the Chief Financial Officer of Amicus Therapeutics, Inc. a biotechnology company, from October 2006 to October 2009. In prior
positions, he spent six years as Corporate Controller of Biogen Inc., a biotechnology company, and six years in various senior financial
roles at E.I. du Pont de Nemours and Company, a chemical, petroleum and biotechnology company, in the U.S. and Asia.
on Mr. Dentzer's appointment, Michael H. Tardugno, Celsion's Executive Chairman, said "We are delighted to welcome
such a talented executive to our Board of Directors. Mr. Dentzer brings a wealth of public company experience, not only leading Curis,
but also as CFO of several well-known development-stage biotechnology companies. We look forward to his valuable advice as we advance
GEN-1 along the clinical and regulatory pathway in ovarian cancer and further develop PLACCINE, our nucleic acid vaccine platform."
Dentzer said, "I am looking forward to supporting Imunon's talented management team and to working collaboratively with my
fellow Directors. I am hopeful that I will help play an important part in the company's growth as it advances its immune-oncology
and infectious diseases programs. In particular, my financial and leadership experience with small-cap biotechnology companies should
be helpful in advancing the company's mission and guiding its business strategy."
is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the
body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting
a differentiating approach from conventional therapies.
has two platform technologies: the TheraPlas platform for the development of immunotherapies and other anti-cancer nucleic
acid-based therapies, and the PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The
company's lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently
in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules,
such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the company is conducting preclinical proof-of-concept
studies on a nucleic acid vaccine candidate targeting the SARS-CoV-2 virus in order to validate its PLACCINE platform. Imunon's
platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral
vectors or devices. Imunon will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better
serve patients with difficult-to-treat conditions. For more information on Imunon, visit www.imunon.com.
wishes to inform readers that forward-looking statements in this news release are made pursuant to the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical
trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of
conducting clinical trials; the need for Imunon to evaluate its future development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks
detailed from time to time in Imunon's periodic reports and prospectuses filed with the Securities and Exchange Commission. Imunon
assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information